PMID- 17653575
OWN - NLM
STAT- MEDLINE
DCOM- 20080429
LR  - 20181113
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 134
IP  - 2
DP  - 2008 Feb
TI  - 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome.
PG  - 227-36
AB  - PURPOSE: Variable uptake of 18FDG has been noticed in positron emission 
      tomography (PET) studies of patients with oesophageal adenocarcinoma. The aim of 
      the present study was to investigate biological parameters involved in 18FDG 
      uptake in oesophageal adenocarcinoma for selection of patients with increased 
      18FDG uptake and prediction of prognostic value of 18FDG PET. PATIENTS AND 
      METHODS: Preoperative PET scans were performed in 26 patients with histologically 
      proven oesophageal adenocarcinoma. 18FDG uptake was semiquantitatively measured 
      by SUV(BSAg. )Tumour sections were stained by immunohistochemistry for angiogenic 
      markers (VEGF, CD31), glucose transporter-1 (Glut-1), hexokinase (HK) isoforms, 
      for proliferation marker (Ki67), for macrophage marker (CD68) and for apoptosis 
      marker (cleaved caspase-3). Cell densities, differentiation grade, degree of 
      necrosis and mucus, T-stage and tumour size were assessed. In addition follow-up 
      was analysed. RESULTS: No association was found between 18FDG uptake and 
      angiogenic markers. In contrast, a significant correlation was found between 
      18FDG uptake and Glut-1 expression. No correlations were found between 18FDG 
      uptake and HK isoforms, Ki67 or cleaved caspase-3. Also, no correlations were 
      found between 18FDG uptake and cell density, differentiation grade, CD68, mucus 
      and necrosis. However, there was a significant correlation between 18FDG uptake 
      and tumour size and between 18FDG uptake and tumour recurrence. CONCLUSIONS: 
      Glut-1 expression and tumour size seem parameters associated with 18FDG uptake in 
      patients with biopsy proven oesophageal adenocarcinoma, and may be used to select 
      oesophageal cancer patients in whom 18FDG-PET is of diagnostic value and may 
      predict disease outcome.
FAU - Westerterp, Marinke
AU  - Westerterp M
AD  - Department of Surgery, Academic Medical Centre, University of Amsterdam, 
      Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. mwesterterp@hotmail.com
FAU - Sloof, Gerrit W
AU  - Sloof GW
FAU - Hoekstra, Otto S
AU  - Hoekstra OS
FAU - Ten Kate, Fiebo J W
AU  - Ten Kate FJ
FAU - Meijer, Gerrit A
AU  - Meijer GA
FAU - Reitsma, Johannes B
AU  - Reitsma JB
FAU - Boellaard, Ronald
AU  - Boellaard R
FAU - van Lanschot, J Jan B
AU  - van Lanschot JJ
FAU - Molthoff, Carla F M
AU  - Molthoff CF
LA  - eng
PT  - Journal Article
DEP - 20070725
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adenocarcinoma/*metabolism/secondary
MH  - Aged
MH  - Biomarkers, Tumor/metabolism
MH  - Esophageal Neoplasms/*metabolism/pathology
MH  - Esophagectomy
MH  - Esophagogastric Junction/diagnostic imaging
MH  - Female
MH  - Fluorodeoxyglucose F18/*pharmacokinetics
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/diagnosis
MH  - Positron-Emission Tomography
MH  - Preoperative Care
MH  - Radiopharmaceuticals/*pharmacokinetics
MH  - Tissue Array Analysis
MH  - Tissue Distribution
MH  - Treatment Outcome
EDAT- 2007/07/27 09:00
MHDA- 2008/04/30 09:00
CRDT- 2007/07/27 09:00
PHST- 2007/04/26 00:00 [received]
PHST- 2007/06/27 00:00 [accepted]
PHST- 2007/07/27 09:00 [pubmed]
PHST- 2008/04/30 09:00 [medline]
PHST- 2007/07/27 09:00 [entrez]
AID - 10.1007/s00432-007-0275-0 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2008 Feb;134(2):227-36. doi: 10.1007/s00432-007-0275-0. 
      Epub 2007 Jul 25.